Rituximab Use in Adult Glomerulopathies and Its Rationale

Overview

Journal J Bras Nefrol

Specialty Nephrology

Date 2020 Jan 7

PMID 31904761

Citations 11

Authors

Joana Eugenio Santos

David Fiel

Ricardo Santos

Rita Vicente

Rute Aguiar

Iolanda Santos

Manuel Amoedo

Carlos Pires

Affiliations

Soon will be listed here.

Abstract

Glomerulopathies are one of the leading causes of end-stage renal disease. In the last years, clinical research has made significant contributions to the understanding of such conditions. Recently, rituximab (RTX) has appeared as a reasonably safe treatment. The Kidney Disease: Improving Global Outcomes guidelines (KDIGO) recommended RTX only as initial treatment in antineutrophil cytoplasm antibody associated vasculitis (AAV) and in non-responders patients with lupus nephritis (LN), but these guidelines have not been updated since 2012. Nowadays, RTX seems to be at least as effective as other immunosuppressive regimens in idiopathic membranous nephropathy (IMN). In minimal-change disease, (MCD) this drug might allow a long-lasting remission period in steroid-dependent or frequently relapsing patients. Preliminary results support the use of RTX in patients with pure membranous LN and immunoglobulin-mediated membranoproliferative glomerulonephritis (MPGN), but not in patients with class III/IV LN or complement-mediated MPGN. No conclusion can be drawn in idiopathic focal segmental glomerulosclerosis (FSGS) and anti-glomerular basement membrane antibody glomerulonephritis (anti-GBM GN) because studies are small, heterogeneous, and scarce. Lastly, immunosuppression including RTX is not particularly useful in IgA nephropathy. This review presents the general background, outcomes, and safety for RTX treatment in different glomerulopathies. In this regard, we describe randomized controlled trials (RCTs) performed in adults, whenever possible. A literature search was performed using clinicaltrials.gov and PubMed.

Citing Articles

Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.

Naipaul R, Marques C, Ng J, Barbour S, Lo C, Hildebrand A Can J Kidney Health Dis. 2023; 10:20543581231190227.

PMID: 37581108 PMC: 10423446. DOI: 10.1177/20543581231190227.

Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.

Ma X, Fang L, Sheng L, Zhou X, Bai S, Zang X Ren Fail. 2023; 45(1):2237124.

PMID: 37482915 PMC: 10367573. DOI: 10.1080/0886022X.2023.2237124.

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.

Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G Front Immunol. 2023; 14:1117699.

PMID: 37138867 PMC: 10150407. DOI: 10.3389/fimmu.2023.1117699.

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.

Chen P, Mao M, Wang C, Zhang X, Zhao X, Gao Y Front Endocrinol (Lausanne). 2023; 14:1044782.

PMID: 36875477 PMC: 9974647. DOI: 10.3389/fendo.2023.1044782.

Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.

Chen D, Helmuth M, Smith A, Canetta P, Ayoub I, Mucha K Am J Kidney Dis. 2023; 81(6):695-706.e1.

PMID: 36608921 PMC: 10200745. DOI: 10.1053/j.ajkd.2022.11.012.

References

Davies R, Sangle S, Jordan N, Aslam L, Lewis M, Wedgwood R . Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013; 22(6):574-82. DOI: 10.1177/0961203313483376. View

Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N . Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009; 4(8):1317-23. PMC: 2723972. DOI: 10.2215/CJN.00570109. View

Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G . Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018; 9(48):28799-28804. PMC: 6034752. DOI: 10.18632/oncotarget.25612. View

Ruggenenti P, Fervenza F, Remuzzi G . Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017; 13(9):563-579. DOI: 10.1038/nrneph.2017.92. View

Alberici F, Smith R, Jones R, Roberts D, C Willcocks L, Chaudhry A . Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2014; 54(7):1153-60. PMC: 4473766. DOI: 10.1093/rheumatology/keu452. View

Santoro D, Pellicano V, Visconti L, Trifiro G, Cernaro V, Buemi M . Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opin Biol Ther. 2015; 15(8):1119-43. DOI: 10.1517/14712598.2015.1045870. View

Suarez-Fueyo A, Bradley S, Klatzmann D, Tsokos G . T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017; 13(6):329-343. DOI: 10.1038/nrneph.2017.34. View

Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K . Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore). 2014; 93(29):e300. PMC: 4602588. DOI: 10.1097/MD.0000000000000300. View

Narayanan M, Casimiro I, Pichler R . A unique way to treat Goodpasture's disease. BMJ Case Rep. 2014; 2014. PMC: 4244353. DOI: 10.1136/bcr-2014-206220. View

10.

Rudnicki M . Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. Biomed Res Int. 2017; 2017:2180508. PMC: 5440792. DOI: 10.1155/2017/2180508. View

11.

Ishiguro H, Hashimoto T, Akata M, Suzuki S, Azushima K, Kobayashi Y . Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med. 2013; 52(10):1079-83. DOI: 10.2169/internalmedicine.52.9325. View

12.

Holdsworth S, Gan P, Kitching A . Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol. 2016; 12(4):217-31. DOI: 10.1038/nrneph.2016.18. View

13.

Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N . Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10):2232-2273. PMC: 5656728. DOI: 10.1007/s12325-017-0612-x. View

14.

Mallat S, Itani H, Abou-Mrad R, Abou Arkoub R, Tanios B . Rituximab use in adult primary glomerulopathy: where is the evidence?. Ther Clin Risk Manag. 2016; 12:1317-27. PMC: 5010164. DOI: 10.2147/TCRM.S114316. View

15.

Tomas N, Beck Jr L, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014; 371(24):2277-2287. PMC: 4278759. DOI: 10.1056/NEJMoa1409354. View

16.

Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly J, Alanio A . ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9):2397-404. DOI: 10.1093/jac/dkw157. View

17.

Salvadori M, Rosso G . Update on immunoglobulin A nephropathy, Part I: Pathophysiology. World J Nephrol. 2015; 4(4):455-67. PMC: 4561843. DOI: 10.5527/wjn.v4.i4.455. View

18.

Puechal X, Pagnoux C, Perrodeau E, Hamidou M, Boffa J, Kyndt X . Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis Rheumatol. 2015; 68(3):690-701. DOI: 10.1002/art.39450. View

19.

Lemahieu W, Ombelet S, Lerut E, Jamar S, Sprangers B . Reversal of Dialysis-Dependent Anti-Glomerular Basement Membrane Disease Using Plasma Exchange, Glucocorticosteroids, and Rituximab. Kidney Int Rep. 2018; 3(5):1229-1232. PMC: 6127412. DOI: 10.1016/j.ekir.2018.04.015. View

20.

Banchereau J, Rousset F . Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol. 1992; 52:125-262. DOI: 10.1016/s0065-2776(08)60876-7. View